Volume 15, Issue 6, Pages 601-611 (May 2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial  Prof John Primrose, MD, Stephen Falk, MD, Meg Finch-Jones, MD, Prof Juan Valle, FRCP, Derek O'Reilly, FRCS, Prof Ajith Siriwardena, MD, Joanne Hornbuckle, MD, Mark Peterson, FRCS, Myrddin Rees, MS, Tim Iveson, MD, Tamas Hickish, MD, Rachel Butler, FRCPath, Louise Stanton, MSc, Elizabeth Dixon, MSc, Louisa Little, RN, Megan Bowers, MSc, Siân Pugh, MRCS, Prof O James Garden, MD, Prof David Cunningham, MD, Prof Tim Maughan, MD, John Bridgewater, PhD  The Lancet Oncology  Volume 15, Issue 6, Pages 601-611 (May 2014) DOI: 10.1016/S1470-2045(14)70105-6 Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet Oncology 2014 15, 601-611DOI: (10.1016/S1470-2045(14)70105-6) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier curves of progression-free survival (A) and overall survival (B) by treatment group in KRAS exon 2 wild-type patients only The Lancet Oncology 2014 15, 601-611DOI: (10.1016/S1470-2045(14)70105-6) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 3 HRs for progression-free survival with chemotherapy alone versus chemotherapy and cetuximab, according to prespecified subgroups The subgroups are based on baseline characteristics. The size of the square corresponds to the amount of information in each subgroup. Data are missing for some patients in some subgroups. HR=hazard ratio. CEA=carcinoembryonic antigen. The Lancet Oncology 2014 15, 601-611DOI: (10.1016/S1470-2045(14)70105-6) Copyright © 2014 Elsevier Ltd Terms and Conditions